Home     About Us     Team     Products     News     Contact     FAQ     Account

PARP Inhibitors

Lynparza (olaparib)

Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers...Wikipedia

 

 

Manufacturer's Website: Lynparza                                                                                                                                       Average retail cost: $13,400/month

Rubraca (rucaparib)

Rucaparib (brand name Rubraca) is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). In December 2016, the U.S. FDA granted an accelerated approval for use in cases of pretreated advanced ovarian cancer...Wikipedia

 

 

Manufacturer's Website: Rubraca                                                                                                                                     Average retail cost: $14,600/month

Zejula (niraparib)

Niraparib (trade name Zejula) is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer...Wikipedia

 

 

Manufacturer's Website: Zejula                                                                                                                                     Average retail cost: $15,400/month

Copyright 2006-2020 Automated Clinical Guidelines, LLC. All rights reserved.